Stockreport

Fulcrum Therapeutics Announces Publication of Results from Phase 2b Clinical Trial of Losmapimod in Facioscapulohumeral muscular dystrophy (ReDUX4) in The Lancet Neurology

Fulcrum Therapeutics, Inc.  (FULC) 
Last fulcrum therapeutics, inc. earnings: 3/5 07:00 am Check Earnings Report
PDF ? Phase 2b ReDUX4 clinical trial indicates improvements in functional, structural, and patient-reported outcomes; findings informed the design and choice of efficacy end [Read more]